1. Home
  2. Syndicated Research

  3. Vulvodynia Treatment Market Analysis 2019

Vulvodynia Treatment Market

Vulvodynia Treatment Market: Nerve Block to Grow in Popularity Among Women Owing to Growing Depression Cases: Global Industry Analysis (2013 - 2017) & Opportunity Assessment (2018 - 2028)

Ask The Analyst Customization Available Request Methodology

There is an increasing tendency of women who have observed chronic vulvar pain once in a lifetime. If the pain is persistent for more than three months and has no apparent cause, it is called vulvodynia. It is estimated that 16% of women in the U.S. will have Vulvodynia at some point in their lives. According to the National Center for Biotechnology Information, U.S. National Library of Medicine, 17.9% of women reported symptoms suggestive of past Vulvodynia in 2013. Based on an analysis, 101,007 women in the 4-county area are estimated to have vulvar pain consistent with Vulvodynia, with another 218,219 having a history of such pain that has since resolved. As a result of these factors, the demand for the drugs is constantly rising. The drug type and its use is measured by the level of pain that is caused of vulvodynia. Although it is a chronic disease, at times even the minutest of pain can cause depression and anxiety among women.

Anticonvulsant to be the most used drug

Anticonvulsant is a type of medication that is used for controlling seizures or stop an ongoing series of seizures (convulsions). In Vulvodynia treatment, anticonvulsant is the most prescribed drug. Gabapentin is most reliable anticonvulsant drug available in vulvodynia treatment. Gabapentin is a drug which has long been recognized in chronic pain management as an effective way of curing pain. It contains tablets taken by mouth and works well for pain related to the nerve. The tablets are prescribed for a number of conditions impacting the central nervous system and they influence pain at the level of the spinal cord. Pregabalin is another anticonvulsant drug. It is very similar to gabapentin; however, it is reported to have fewer side effects and is possibly more operative.

vulvodynia-treatment-market.jpg

Tricyclic antidepressant to rise in consumption

Tricyclic antidepressants (TCAs) are a class of medications that are used primarily as antidepressants. These can be prescribed by your doctor in doses lower than those used to treat depression. The drugs are used because they alter the way in which the nerve fibres transmit the sensation of pain, not because the doctor thinks it's all in your mind. It is often necessary to continue with treatment for 3-6 months. Examples of tablets include amitriptyline, nortriptyline and dothiepin. Other antidepressants namely venlafaxine can also be tried. As the treatment of vulvodynia is mainly centred at placebo, antidepressants are the first of form of medical treatments given to a patient in case of minor pains.

Use of local anaesthetic to rise globally

Local anaesthetics are generally applied externally to the skin. This medication originates in a form of gel or cream. They may be used before sexual intercourse to provide short-term pain relief, or they can be used for extended periods. Local anaesthetic is used topically to introitus, which decrease hypersensitivity. This medication need to apply before intercourse or nightly on a cotton ball in the introitus. Lidocaine gel or cream is considered to be the best local anaesthetic cream or gel for vulvodynia.

Global Healthcare Sector Outlook

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare

  • Current expenditure on health, % of gross domestic product

  • Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs)

  • Annual growth rate of current expenditure on health, per capita, in real terms

  • Out-of-pocket expenditure, % of current expenditure on health

  • Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs)

  • Physicians, Density per 1000 population (head counts)

  • Nurses, Density per 1000 population (head counts)

  • Total hospital beds, per 1000 population

  • Curative (acute) care beds, per 1000 population

  • Medical technology, Magnetic Resonance Imaging units, total, per million population

  • Medical technology, Computed Tomography scanners, total, per million population

Research Methodology

FMI utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.

Standard Report Structure

  • Executive Summary

  • Market Definition

  • Macro-economic analysis

  • Parent Market Analysis

  • Market Overview

  • Forecast Factors

  • Segmental Analysis and Forecast

  • Regional Analysis

  • Competition Analysis

Market Taxonomy

The vulvodynia treatment market has been segmented on the following:

Drug Class

Mode of Administration

Distribution Channel

Region

  • Local Anesthetic

  • Anticonvulsant

  • Tricyclic Antidepressant

  • Hormones

  • Serotonin-norepinephrine Reuptake Inhibitors (SNRI)

  • Nerve Block

  • Others

  • Oral

  • Topical

  • Injection

  • Hospital Pharmacies

  • Retail Pharmacies

  • Drug Store

  • Online Pharmacies

  • North America

  • Latin America

  • Western Europe

  • Eastern Europe

  • APEJ

  • Japan

  • MEA

Specific Report Inputs

The analyst has checked the prevalence of vulvodynia among the women of 18 to 45 years of age. The main countries in every region have been gauged to check the prevalence rate in every country. The co-morbidity rate has also been considered country-wise. The annual treatment cost along with the volume consumed has been taken into consideration to come to the data in the report.

Vulvodynia Treatment Market Reports - Table of Contents

1. Executive Summary

1.1. Market Overview

1.2. Market Analysis

1.3. FMI Analysis and Recommendations

1.4. Wheel of Fortune

2. Market Introduction

2.1. Market Taxonomy

2.2. Market Definition

3. Vulvodynia Treatment Market View Point

3.1. Macro-Economic Factors

3.2. Opportunity Analysis

3.3. Occurrence of Vulvodynia

3.4. Regulatory Scenario

4. Vulvodynia Treatment Market Dynamics

4.1. Drivers

4.2. Restraints

4.3. Opportunities

4.4. Trends

5. North America Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028

5.1. Introduction

5.2. Regional Market Dynamics

5.3. Historical Market Size (US$ Mn) By Country, 2013-2017

5.3.1. U.S.

5.3.2. Canada

5.4. Market Size (US$ Mn) Forecast By Country, 2018-2028

5.4.1. U.S.

5.4.2. Canada

5.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017

5.5.1. Anticonvulsant

5.5.2. Tricyclic Antidepressant

5.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)

5.5.4. Hormone

5.5.5. Nerve Block

5.5.6. Local Anesthetic

5.5.7. Others

5.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028

5.6.1. Anticonvulsant

5.6.2. Tricyclic Antidepressant

5.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)

5.6.4. Hormone

5.6.5. Nerve Block

5.6.6. Local Anesthetic

5.6.7. Others

5.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017

5.7.1. Oral

5.7.2. Topical

5.7.3. Injectable

5.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028

5.8.1. Oral

5.8.2. Topical

5.8.3. Injectable

5.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017

5.9.1. Hospital Pharmacies

5.9.2. Retail Pharmacies

5.9.3. Drug Stores

5.9.4. Online Pharmacies

5.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028

5.10.1. Hospital Pharmacies

5.10.2. Retail Pharmacies

5.10.3. Drug Stores

5.10.4. Online Pharmacies

5.11. Drivers and Restraints: Impact Analysis

5.12. Market Attractiveness Analysis

5.12.1. By Country

5.12.2. By Drug Class

5.12.3. By Mode Of Administration

5.12.4. By Distribution Channel

5.13. Key Representative Market Participants

5.14. Key Participants Market Presence (Intensity Map)

6. Latin America Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028

6.1. Introduction

6.2. Regional Market Dynamics

6.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017

6.3.1. Brazil

6.3.2. Mexico

6.3.3. Rest of Latin America

6.4. Market Size (US$ Mn) Forecast By Country, 2018–2028

6.4.1. Brazil

6.4.2. Mexico

6.4.3. Rest of Latin America

6.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017

6.5.1. Anticonvulsant

6.5.2. Tricyclic Antidepressant

6.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)

6.5.4. Hormone

6.5.5. Nerve Block

6.5.6. Local Anesthetic

6.5.7. Others

6.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028

6.6.1. Anticonvulsant

6.6.2. Tricyclic Antidepressant

6.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)

6.6.4. Hormone

6.6.5. Nerve Block

6.6.6. Local Anesthetic

6.6.7. Others

6.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017

6.7.1. Oral

6.7.2. Topical

6.7.3. Injectable

6.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028

6.8.1. Oral

6.8.2. Topical

6.8.3. Injectable

6.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017

6.9.1. Hospital Pharmacies

6.9.2. Retail Pharmacies

6.9.3. Drug Stores

6.9.4. Online Pharmacies

6.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028

6.10.1. Hospital Pharmacies

6.10.2. Retail Pharmacies

6.10.3. Drug Stores

6.10.4. Online Pharmacies

6.11. Drivers and Restraints: Impact Analysis

6.12. Market Attractiveness Analysis

6.12.1. By Country

6.12.2. By Drug Class

6.12.3. By Mode Of Administration

6.12.4. By Distribution Channel

6.13. Key Representative Market Participants

6.14. Key Participants Market Presence (Intensity Map)

7. Western Europe Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028

7.1. Introduction

7.2. Regional Market Dynamics

7.3. Historical Market Size (US$ Mn) By Country, 2013-2017

7.3.1. Germany

7.3.2. United Kingdom

7.3.3. France

7.3.4. Italy

7.3.5. Spain

7.3.6. Nordic Region

7.3.7. Rest of Western Europe

7.4. Market Size (US$ Mn) Forecast By Country, 2018-2028

7.4.1. Germany

7.4.2. United Kingdom

7.4.3. France

7.4.4. Italy

7.4.5. Spain

7.4.6. Nordic Region

7.4.7. Rest of Western Europe

7.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017

7.5.1. Anticonvulsant

7.5.2. Tricyclic Antidepressant

7.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)

7.5.4. Hormone

7.5.5. Nerve Block

7.5.6. Local Anesthetic

7.5.7. Others

7.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028

7.6.1. Anticonvulsant

7.6.2. Tricyclic Antidepressant

7.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)

7.6.4. Hormone

7.6.5. Nerve Block

7.6.6. Local Anesthetic

7.6.7. Others

7.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017

7.7.1. Oral

7.7.2. Topical

7.7.3. Injectable

7.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028

7.8.1. Oral

7.8.2. Topical

7.8.3. Injectable

7.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017

7.9.1. Hospital Pharmacies

7.9.2. Retail Pharmacies

7.9.3. Drug Stores

7.9.4. Online Pharmacies

7.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028

7.10.1. Hospital Pharmacies

7.10.2. Retail Pharmacies

7.10.3. Drug Stores

7.10.4. Online Pharmacies

7.11. Drivers and Restraints: Impact Analysis

7.12. Market Attractiveness Analysis

7.12.1. By Country

7.12.2. By Drug Class

7.12.3. By Mode Of Administration

7.12.4. By Distribution Channel

7.13.Key Representative Market Participants

7.14.Key Participants Market Presence (Intensity Map)

8. Eastern Europe Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028

8.1. Introduction

8.2. Regional Market Dynamics

8.3. Historical Market Size (US$ Mn) By Country, 2013-2017

8.3.1. Russia

8.3.2. Poland

8.3.3. Rest of Eastern Europe

8.4. Market Size (US$ Mn) Forecast By Country, 2018-2028

8.4.1. Russia

8.4.2. Poland

8.4.3. Rest of Eastern Europe

8.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017

8.5.1. Anticonvulsant

8.5.2. Tricyclic Antidepressant

8.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)

8.5.4. Hormone

8.5.5. Nerve Block

8.5.6. Local Anesthetic

8.5.7. Others

8.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028

8.6.1. Anticonvulsant

8.6.2. Tricyclic Antidepressant

8.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)

8.6.4. Hormone

8.6.5. Nerve Block

8.6.6. Local Anesthetic

8.6.7. Others

8.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017

8.7.1. Oral

8.7.2. Topical

8.7.3. Injectable

8.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028

8.8.1. Oral

8.8.2. Topical

8.8.3. Injectable

8.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017

8.9.1. Hospital Pharmacies

8.9.2. Retail Pharmacies

8.9.3. Drug Stores

8.9.4. Online Pharmacies

8.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028

8.10.1. Hospital Pharmacies

8.10.2. Retail Pharmacies

8.10.3. Drug Stores

8.10.4. Online Pharmacies

8.11. Drivers and Restraints: Impact Analysis

8.12. Market Attractiveness Analysis

8.12.1. By Country

8.12.2. By Drug Class

8.12.3. By Mode Of Administration

8.12.4. By Distribution Channel

8.13. Key Representative Market Participants

8.14. Key Participants Market Presence (Intensity Map)

9. Asia Pacific Excluding Japan Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028

9.1. Introduction

9.2. Regional Market Dynamics

9.3. Historical Market Size (US$ Mn) By Country, 2013-2017

9.3.1. China

9.3.2. India

9.3.3. Australia and New Zealand

9.3.4. ASEAN

9.3.5. Rest of APEJ

9.4. Market Size (US$ Mn) Forecast By Country, 2018-2028

9.4.1. China

9.4.2. India

9.4.3. Australia and New Zealand

9.4.4. ASEAN

9.4.5. Rest of APEJ

9.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017

9.5.1. Anticonvulsant

9.5.2. Tricyclic Antidepressant

9.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)

9.5.4. Hormone

9.5.5. Nerve Block

9.5.6. Local Anesthetic

9.5.7. Others

9.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028

9.6.1. Local Anesthetic

9.6.2. Anticonvulsant

9.6.3. Tricyclic Antidepressant

9.6.4. Hormones

9.6.5. Serotonin-norepinephrine reuptake inhibitors (SNRI)

9.6.6. Nerve Block

9.6.7. Others

9.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017

9.7.1. Oral

9.7.2. Topical

9.7.3. Injectable

9.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028

9.8.1. Oral

9.8.2. Topical

9.8.3. Injectable

9.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017

9.9.1. Hospital Pharmacies

9.9.2. Retail Pharmacies

9.9.3. Drug Stores

9.9.4. Online Pharmacies

9.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028

9.10.1. Hospital Pharmacies

9.10.2. Retail Pharmacies

9.10.3. Drug Stores

9.10.4. Online Pharmacies

9.11. Drivers and Restraints: Impact Analysis

9.12. Market Attractiveness Analysis

9.12.1. By Country

9.12.2. By Drug Class

9.12.3. By Mode Of Administration

9.12.4. By Distribution Channel

9.13. Key Representative Market Participants

9.14. Key Participants Market Presence (Intensity Map)

10. Japan Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028

10.1. Introduction

10.2. Regional Market Dynamics

10.3. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017

10.3.1. Anticonvulsant

10.3.2. Tricyclic Antidepressant

10.3.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)

10.3.4. Hormone

10.3.5. Nerve Block

10.3.6. Local Anesthetic

10.3.7. Others

10.4. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028

10.4.1. Anticonvulsant

10.4.2. Tricyclic Antidepressant

10.4.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)

10.4.4. Hormone

10.4.5. Nerve Block

10.4.6. Local Anesthetic

10.4.7. Others

10.5. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017

10.5.1. Oral

10.5.2. Topical

10.5.3. Injectable

10.6. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028

10.6.1. Oral

10.6.2. Topical

10.6.3. Injectable

10.7. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017

10.7.1. Hospital Pharmacies

10.7.2. Retail Pharmacies

10.7.3. Drug Stores

10.7.4. Online Pharmacies

10.8. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028

10.8.1. Hospital Pharmacies

10.8.2. Retail Pharmacies

10.8.3. Drug Stores

10.8.4. Online Pharmacies

10.9. Drivers and Restraints: Impact Analysis

10.10. Market Attractiveness Analysis

10.10.1. By Drug Class

10.10.2. By Mode Of Administration

10.10.3. By Distribution Channel

10.11. Key Representative Market Participants

10.12. Key Participants Market Presence (Intensity Map)

11. Middle East and Africa Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028

11.1. Introduction

11.2. Regional Market Dynamics

11.2.1. Drivers

11.2.2. Restraints

11.2.3. Trends

11.3. Historical Market Size (US$ Mn) Analysis By Country, 2013–2017

11.3.1. GCC Countries

11.3.2. South Africa

11.3.3. Rest of MEA

11.4. Market Size (US$ Mn) Forecast By Country, , 2018–2028

11.4.1. GCC Countries

11.4.2. South Africa

11.4.3. Rest of MEA

11.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017

11.5.1. Anticonvulsant

11.5.2. Tricyclic Antidepressant

11.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)

11.5.4. Hormone

11.5.5. Nerve Block

11.5.6. Local Anesthetic

11.5.7. Others

11.6. Market Size (US$ Mn) Forecast and By Drug Class, 2018–2028

11.6.1. Anticonvulsant

11.6.2. Tricyclic Antidepressant

11.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)

11.6.4. Hormone

11.6.5. Nerve Block

11.6.6. Local Anesthetic

11.6.7. Others

11.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017

11.7.1. Oral

11.7.2. Topical

11.7.3. Injectable

11.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028

11.8.1. Oral

11.8.2. Topical

11.8.3. Injectable

11.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017

11.9.1. Hospital Pharmacies

11.9.2. Retail Pharmacies

11.9.3. Drug Stores

11.9.4. Online Pharmacies

11.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028

11.10.1. Hospital Pharmacies

11.10.2. Retail Pharmacies

11.10.3. Drug Stores

11.10.4. Online Pharmacies

11.11. Drivers and Restraints: Impact Analysis

11.12. Market Attractiveness Analysis

11.12.1. By Country

11.12.2. By Drug Class

11.12.3. By Mode Of Administration

11.12.4. By Distribution Channel

11.13. Key Representative Market Participants

11.14. Key Participants Market Presence (Intensity Map)

12. Forecast Factors: Relevance and Impact

13. Forecast Assumptions

14. Competition Landscape

14.1. Competition Dashboard

14.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

14.2.1. GlaxoSmithKline plc.

14.2.2. AstraZeneca Plc.

14.2.3. Eli Lilly and Company

14.2.4. Merck & Co., Inc.

14.2.5. Pfizer Inc.

14.2.6. Johnson & Johnson Services, Inc.

14.2.7. Allergan plc.

14.2.8. Depomed Inc.

14.2.9. Par pharmaceutical

14.2.10. Vertical pharmaceutical

15. Global Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Region

15.1. Introduction / Key Findings

15.2. Historical Market Size (US$ Mn) Analysis By Region, 2013–2017

15.2.1. North America

15.2.2. Western Europe

15.2.3. Eastern Europe

15.2.4. Latin America

15.2.5. Asia Pacific Excluding Japan

15.2.6. Japan

15.2.7. Middle East and Africa

15.3. Market Size (US$ Mn) Forecast By Region, 2018–2028

15.3.1. North America

15.3.2. Western Europe

15.3.3. Eastern Europe

15.3.4. Latin America

15.3.5. Asia Pacific Excluding Japan

15.3.6. Japan

15.3.7. Middle East and Africa

15.4. Key Trends / Developments

15.5. Market Attractiveness Analysis By Region

16. Global Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Drug Class

16.1. Introduction

16.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2017

16.2.1. Anticonvulsant

16.2.2. Tricyclic Antidepressant

16.2.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)

16.2.4. Hormone

16.2.5. Nerve Block

16.2.6. Local Anesthetic

16.2.7. Others

16.3. Market Size (US$ Mn) Forecast By Drug Class, 2018–2028

16.3.1. Anticonvulsant

16.3.2. Tricyclic Antidepressant

16.3.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)

16.3.4. Hormone

16.3.5. Nerve Block

16.3.6. Local Anesthetic

16.3.7. Others

16.4. Market Attractiveness Analysis By Drug Class

17. Global Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Mode Of Administration

17.1. Introduction

17.2. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2017

17.2.1. Oral

17.2.2. Topical

17.2.3. Injectable

17.3. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2018–2028

17.3.1. Oral

17.3.2. Topical

17.3.3. Injectable

17.4. Market Attractiveness Analysis By Mode Of Administration

18. Global Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

18.1. Introduction

18.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2017

18.2.1. Hospital Pharmacies

18.2.2. Retail Pharmacies

18.2.3. Drug Stores

18.2.4. Online Pharmacies

18.3. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2018–2028

18.3.1. Hospital Pharmacies

18.3.2. Retail Pharmacies

18.3.3. Drug Stores

18.3.4. Online Pharmacies

18.4. Market Attractive Analysis By Distribution Channel

19. Global Vulvodynia Treatment Market Analysis 2013–2017 and Forecast 2018–2028

19.1. Market Size and Y-o-Y Growth

19.2. Absolute $ Opportunity

19.3. Value Chain

20. Assumptions and Acronyms Used

21. Research Methodology

Vulvodynia Treatment Market Reports - List of Tables

Table 01: North America Vulvodynia Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018-2028  By Country

Table 02: North America Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 03: North America Vulvodynia Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018-2028, By mode of administration

Table 04: North America Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2028, By Distribution Channel

Table 05: Latin America Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2028, By Country

Table 06: Latin America Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2028, By Drug Type

Table 07: Latin America Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2028, By mode of administration

Table 08: Latin America Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2028, By Distribution Channel

Table 09: Western Europe Vulvodynia Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018–2028, By Country

Table 10: Western Europe Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2028, By Drug Type

Table 11: Western Europe Vulvodynia Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018–2028, By mode of administration

Table 12: Western Europe Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2028, By Distribution Channel

Table 13: Eastern Europe Vulvodynia Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018–2028, By Country

Table 14: Eastern Europe Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2028, By Drug Type

Table 15: Eastern Europe Vulvodynia Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018–2028, By mode of administration

Table 16: Eastern Europe Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2028, By Distribution Channel

Table 17: Asia Pacific Excluding Japan Vulvodynia Treatment Market size (US$ Mn) Analysis, 2013–2017 and Forecast 2018–2028, By Country

Table 18: Asia Pacific Excluding Japan Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2028, By Drug Type

Table 19: Asia Pacific Excluding Japan Vulvodynia Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018–2028, By mode of administration

Table 20: Asia Pacific Excluding Japan Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2028, By Distribution Channel

Table 21: Japan Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2028, By Drug Type

Table 22: Japan Vulvodynia Treatment Market size (US$ Mn)Analysis-22013–2017 and Forecast 2018–2028, By mode of administration

Table 23: Japan Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2028, By Distribution Channel

Table 24: Middle East and Africa  Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2028, By Country

Table 25: Middle East and Africa  Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2028, By Drug Type

Table 26: Middle East and Africa  Vulvodynia Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018–2028, By mode of administration

Table 27: Middle East and Africa  Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2028, By Distribution Channel

Table 28: Global Vulvodynia Treatment Market Size (US$ Mn) Forecast By Region, 2013-2018

Table 29: Global Vulvodynia Treatment Market Size Value (US$ Mn) Analysis 2012–2016 and Forecast 2018–2028 , By Drug Type

Table 30: Global Vulvodynia Treatment Market size (US$ Mn) Analysis 2018–2028 and Forecast 2017–2027, By Animal Type

Table 31: Global Vulvodynia Treatment Market size (US$ Mn) Analysis 2012–2016 and Forecast 2018–2028, By Distribution Channel

Vulvodynia Treatment Market Reports - List of Figures

Figure 01: Pain Description by Vulvodynia Patient

Figure 02: Pain Location in Vulvodynia Patient

Figure 03: Additional Conditions Suffered By Vulvodynia Patient

Figure 04: Vulvodynia Treatment Market Split By Country (2017)

Figure 05: Vulvodynia Treatment Market Split By Drug Class (2017)

Figure 06: Vulvodynia Treatment Market Split By Mode of Administration (2017)

Figure 07: Vulvodynia Treatment Market Split By Distribution Channel (2017)

Figure 08: North America Vulvodynia Treatment Market Size Analysis, 2013–2017

Figure 09: North America Vulvodynia Treatment Market Forecast & Y-o-Y growth, 2018–2028

Figure 10: U.S. Vulvodynia Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 11: U.S. Vulvodynia Treatment , Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 12: Canada Vulvodynia Treatment, Market Size (US$ Mn) Analysis, 2013–2017

Figure 13: Canada Vulvodynia Treatment , Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 14: Anticonvulsant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 15: Anticonvulsant Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 16: Tricyclic Antidepressant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 17: Tricyclic Antidepressant Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 18: SNRIs Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 19: SNRIs Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 20: Hormone Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 21: Hormone Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 22: Nerve Block Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 23: Nerve Block Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 24: Local Anesthetic Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 25: Local Anesthetic Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 26: Other Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 27: Other Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 28: North America Vulvodynia Treatment Market Attractiveness Analysis By Country, 2018-2028

Figure 29: North America Vulvodynia Treatment Market Attractiveness Analysis By Drug Class, 2018-2028 

Figure 30: North America Vulvodynia Treatment Market Attractiveness Analysis By Mode of Administration, 2018-2028

Figure 31: North America Vulvodynia Treatment Market Attractiveness Analysis By Distribution Channel, 2018-2028  

Figure 32: Vulvodynia Treatment Market Split By Country (2017)

Figure 33: Vulvodynia Treatment Market Split By Drug Class (2017)

Figure 34: Vulvodynia Treatment Market Split By Mode of Administration (2017)

Figure 35: Vulvodynia Treatment Market Split By Distribution Channel (2017)

Figure 36: Latin America Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 37: Latin America Vulvodynia Treatment Market Forecast & Y-o-Y growth, 2018-2028 

Figure 38: Brazil Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 39: Brazil Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 40: Mexico Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 41: Mexico Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 42: Rest of Latin America Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 43: Rest of Latin America Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 44: Anticonvulsant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 45: Anticonvulsant Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 46: Tricyclic Antidepressant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 47: Tricyclic Antidepressant Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 48: SNRIs Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 49: SNRIs Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 50: Hormone Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2013–2017

Figure 51: Hormone Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 52: Nerve Block Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 53: Nerve Block Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 54: Local Anesthetic Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2013–2017

Figure 55: Local Anesthetic Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 56: Other Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 57: Other Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028 

Figure 58: Latin America Vulvodynia Treatment Market Attractiveness Analysis By Country, 2018-2028 

Figure 59: Latin America Vulvodynia Treatment Market Attractiveness Analysis By Drug Class, 2018-2028 

Figure 60: Latin America Vulvodynia Treatment Market Attractiveness Analysis By Mode of Administration, 2018-2028 

Figure 61: Latin America Vulvodynia Treatment Market Attractiveness Analysis By Distribution Channel, 2018-2028  

Figure 62: Vulvodynia Treatment Market Split By Country (2017)

Figure 63: Vulvodynia Treatment Market Split By Drug Class (2017)

Figure 64: Vulvodynia Treatment Market Split By Mode of Administration (2017)

Figure 65: Vulvodynia Treatment Market Split By Distribution Channel (2017)

Figure 66: Western Europe Vulvodynia Treatment Market Size Analysis, 2013–2017

Figure 67: Western Europe Vulvodynia Treatment Market Forecast & Y-o-Y growth, 2018–2028

Figure 68: U.K. Vulvodynia Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 69: U.K. Vulvodynia Treatment , Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 70: Germany Vulvodynia Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 71: Germany Vulvodynia Treatment , Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 72: France Vulvodynia Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 73: France Vulvodynia Treatment , Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 74: Spain Vulvodynia Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 75: Spain Vulvodynia Treatment , Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 76: Italy Vulvodynia Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 77: Italy Vulvodynia Treatment , Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 78: Rest of Western Europe Vulvodynia Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 79: Rest of Western Europe Vulvodynia Treatment , Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 80: Anticonvulsant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 81: Anticonvulsant Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 82: Tricyclic Antidepressant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 83: Tricyclic Antidepressant Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 84: SNRIs Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 85: SNRIs Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 86: Hormone Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2013–2017

Figure 87: Hormone Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 88: Nerve Block Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 89: Nerve Block Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 90: Local Anesthetic Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2013–2017

Figure 91: Local Anesthetic Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 92: Other Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 93: Other Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 94: Western Europe Vulvodynia Treatment Market Attractiveness Analysis By Country, 2018–2028 

Figure 95: Western Europe Vulvodynia Treatment Market Attractiveness Analysis By Drug Class, 2018–2028 

Figure 96: Western Europe Vulvodynia Treatment Market Attractiveness Analysis By Mode of Administration, 2018–2028 

Figure 97: Western Europe Vulvodynia Treatment Market Attractiveness Analysis By Distribution Channel, 2018–2028 

Figure 98: Vulvodynia Treatment Market Split By Country (2017)

Figure 99: Vulvodynia Treatment Market Split By Drug Class (2017)

Figure 100: Vulvodynia Treatment Market Split By Mode of Administration (2017)

Figure 101: Vulvodynia Treatment Market Split By Distribution Channel (2017)

Figure 102: Eastern Europe Vulvodynia Treatment Market Size Analysis, 2013–2017

Figure 103: Eastern Europe Vulvodynia Treatment Market Forecast & Y-o-Y growth, 2018–2028

Figure 104: Russia Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 105: Russia Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 106: Poland Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 107: Poland Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 108: Rest of Eastern Europe Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 109: Rest of Eastern Europe Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 110: Anticonvulsant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 111: Anticonvulsant Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 112: Tricyclic Antidepressant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 113: Tricyclic Antidepressant Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 114: SNRIs Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 115: SNRIs Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 116: Hormone Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 117: Hormone Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 118: Nerve Block Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 119: Nerve Block Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 120: Local Anesthetic Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 121: Local Anesthetic Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 122: Other Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 123: Other Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2018–2028

Figure 124: Eastern Europe Vulvodynia Treatment Market Attractiveness Analysis By Country, 2018–2028 

Figure 125: Eastern Europe Vulvodynia Treatment Market Attractiveness Analysis By Drug Class, 2018–2028 

Figure 126: Eastern Europe Vulvodynia Treatment Market Attractiveness Analysis By Mode of Administration, 2018–2028 

Figure 127: Eastern Europe Vulvodynia Treatment Market Attractiveness Analysis By Distribution Channel, 2018–2028 

Figure 128: Vulvodynia Treatment Market Split By Country (2017)

Figure 129: Vulvodynia Treatment Market Split By Drug Class (2017)

Figure 130: Vulvodynia Treatment Market Split By Mode of Administration (2017)

Figure 131: Vulvodynia Treatment Market Split By Distribution Channel (2017)

Figure 132: Asia Pacific Excluding Japan Vulvodynia Treatment Market Size Analysis (US$ Mn), 2013–2017

Figure 133: Asia Pacific Excluding Japan Vulvodynia Treatment Market Forecast (US$ Mn) (US$ Mn) & Y-o-Y growth (%), 2018–2028

Figure 134: China Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 135: China Vulvodynia Treatment Market Forecast (US$ Mn) (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 136: India Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 137: India Vulvodynia Treatment Market Forecast (US$ Mn) (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 138: Australia and New Zealand Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 139: Australia and New Zealand Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 140: Rest of APEJ Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 141: Rest of APEJ Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 142: Anticonvulsant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 143: Anticonvulsant Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 144: Tricyclic Antidepressant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 145: Tricyclic Antidepressant Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 146: SNRIs Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 147: SNRIs Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 148: Hormone Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 149: Hormone Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 150: Nerve Block Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 151: Nerve Block Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 152: Local Anesthetic Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 153: Local Anesthetic Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 154: Other Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 155: Other Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 156: Asia Pacific Excluding Japan Vulvodynia Treatment Market Attractiveness Analysis By Country, 2018–2028 

Figure 157: Asia Pacific Excluding Japan Vulvodynia Treatment Market Attractiveness Analysis By Drug Class, 2018–2028 

Figure 158: Asia Pacific Excluding Japan Vulvodynia Treatment Market Attractiveness Analysis By Mode of Administration, 2018–2028 

Figure 159: Asia Pacific Excluding Japan Vulvodynia Treatment Market Attractiveness Analysis By Distribution Channel, 2018–2028 

Figure 160: Vulvodynia Treatment Market Split By Drug Class (2017)

Figure 161: Vulvodynia Treatment Market Split By Mode of Administration (2017)

Figure 162: Vulvodynia Treatment Market Split By Distribution Channel (2017)

Figure 163: Japan Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 164: Japan Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y growth, 2018–2028

Figure 165: Anticonvulsant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 166: Anticonvulsant Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 167: Tricyclic Antidepressant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2012–2016

Figure 168: Tricyclic Antidepressant Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 169: SNRIs Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 170: SNRIs Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 171: Hormone Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 172: Hormone Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 173: Nerve Block Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 174: Nerve Block Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 175: Local Anesthetic Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 176: Local Anesthetic Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 177: Other Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 178: Other Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 179: Japan Vulvodynia Treatment Market Attractiveness Analysis By Drug Class, 2018–2028 

Figure 180: Japan Vulvodynia Treatment Market Attractiveness Analysis By Mode of Administration, 2018–2028 

Figure 181: Japan Vulvodynia Treatment Market Attractiveness Analysis By Distribution Channel, 2018–2028 

Figure 182: Vulvodynia Treatment Market Split By Country (2017)

Figure 183: Vulvodynia Treatment Market Split By Drug Class (2017)

Figure 184: Vulvodynia Treatment Market Split By Mode of Administration (2017)

Figure 185: Vulvodynia Treatment Market Split By Distribution Channel (2017)

Figure 186: Middle East and Africa  Vulvodynia Treatment Market Size Analysis, 2013–2017

Figure 187: Middle East and Africa  Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y growth, 2018–2028

Figure 188: GCC Countries Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 189: GCC Countries Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 190: South Africa Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2012–2016

Figure 191: South Africa Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 192: Rest of MEA Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 193: Rest of MEA Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 194: Anticonvulsant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 195: Anticonvulsant Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 196: Tricyclic Antidepressant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 197: Tricyclic Antidepressant Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 198: SNRIs Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 199: SNRIs Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 200: Hormone Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 201: Hormone Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 202: Nerve Block Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 203: Nerve Block Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 204: Local Anesthetic Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 205: Local Anesthetic Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 206: Other Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2017

Figure 207: Other Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 208: Middle East and Africa  Vulvodynia Treatment Market Attractiveness Analysis By Country, 2018–2028 

Figure 209: Middle East and Africa  Vulvodynia Treatment Market Attractiveness Analysis By Drug Class, 2018–2028 

Figure 210: Middle East and Africa  Vulvodynia Treatment Market Attractiveness Analysis By Mode of Administration, 2018–2028 

Figure 211: Middle East and Africa  Vulvodynia Treatment Market Attractiveness Analysis By Distribution Channel, 2018–2028 

Figure 212: Global Vulvodynia Treatment Market Attractiveness Analysis By Region, 2018–2028 

Figure 213: Global Vulvodynia Treatment Market Attractiveness Analysis By Drug Type, 2018–2028 

Figure 214: Global Vulvodynia Treatment Market Attractiveness Analysis By Animal Type, 2018–2028

Figure 215: Global Vulvodynia Treatment Market Attractiveness Analysis By Distribution Channel, 2018–2028 

Figure 216: Global Vulvodynia Treatment Market Value Analysis and Forecast, 2017–2028 (US$ Mn

Figure 217: Global Vulvodynia Treatment Market Absolute $ Opportunity (US$ Mn), 2017–2028